UCLA Health Jonsson Comprehensive Cancer Center Advances Colorectal and Prostate Cancer Research
UCLA Health Jonsson Comprehensive Cancer Center has reported significant advancements in cancer research, particularly in the areas of colorectal and prostate cancer. For colorectal cancer, researchers are focusing on improving screening methods for younger adults and developing new immunotherapy and vaccine strategies. In prostate cancer, UCLA investigators are utilizing artificial intelligence to precisely map the boundaries of cancerous tissue. This AI-driven approach aims to enhance diagnostic accuracy, refine treatment planning, and improve the effectiveness of surgical procedures. These efforts are part of a broader mission at UCLA to accelerate discoveries that prevent and cure cancer, building on a legacy of transforming scientific hope into tangible progress for patients. The center has also been instrumental in the development of targeted therapies like Ibrance, which has redefined treatment for advanced ER+/HER2- breast cancer since its FDA approval in 2015.
